SZNSL-RRecruiting

A registry study to collect data on secondary lymphomas of the central nervous system

Gender
Women and men
Age
All ages
Trial type
Observational
Line of therapy
First line
Phase
Phase IV

What is this trial about?

Secondary central nervous system lymphomas (SZNSL) are malignant diseases of the central nervous system (CNS) that develop in the CNS only as a result (secondarily) of lymphoma in other parts of the body (where the disease is primary). To date, there are no universally accepted treatment principles for these conditions. The goal of the SZNSL-R study is to document, systematically analyze, and compare the various current treatment strategies and clinical outcomes for SZNSL. Patients with SZNSL are eligible to participate in the study, regardless of their previous treatment.

Detailed description

Secondary CNS lymphoma (SCNSL) is a specific form of non-Hodgkin lymphoma and involves abnormal lymphocytes that originated from a lymphoma initially located outside the CNS and have spread to the brain and/or spinal cord (secondary). In contrast, primary CNS lymphomas arise directly in the brain or spinal cord. Lymphocytes are a type of white blood cell that is part of the immune system. The exact cause of the disease is unknown, but certain risk factors, such as a weakened immune system, may play a role. Symptoms include, among others, personality changes, dementia, depression, neurological symptoms, and headaches. Treatment typically involves intensive chemotherapy with the goal of bringing the disease into remission (reduction in cancer cells). Methotrexate is used in particular because it can cross the blood-brain barrier. Chemotherapy can also be combined with immunotherapy, such as rituximab. Various other medications or treatment strategies are also used. However, there is currently no uniform standard for how treatment should be carried out in detail.

The SZNSL-R study is an observational study (registry) conducted in hospitals, outpatient clinics, and oncology practices. This means that no specific therapy is prescribed or administered as part of the study, and the course of the patients’ disease is documented solely through routine examinations. The goal is to collect data on the treatment of SZNSL and to analyze it comparatively. This includes demographic data as well as information on pre-existing conditions, disease progression, patterns of spread, prior treatments, and general health status. This study aims to gather data on the efficacy and safety of various treatment approaches and to compare them further. Observations as part of the study will be conducted for up to 3 years, during which the efficacy of the therapies and the occurrence of side effects from the various treatments will be documented.

All patients with SZNSL are eligible to participate in this study. Inclusion in the study is possible regardless of prior therapy.

Facts

  1. What is the disease: secondary CNS lymphoma (SCNSL).
  2. Cancer characteristics: Regardless of previous therapies.
  3. What the study investigates: Documentation of treatment strategies and clinical outcomes; only drugs that are already approved will be tested as part of the study.
  4. Study objective: Comparison and evaluation of different treatment approaches and their clinical outcomes.
  5. How long will the study last: Follow-up for up to approximately 3 years.
  6. Study characteristics: Non-interventional observational study (registry), prospective data collection.

Trial sites

1 trial site in Germany is listed.

  • Charité – Universitätsmedizin Berlin

    12200 Berlin

    Recruiting

This list is compiled to the best of our knowledge but without guarantee: it may be incomplete, and a site's recruitment status can change at any time.

Medical editorial team

  • Dr. med. Sebastian SommerSpecialist in internal medicine with a focus on hematology and oncology
  • PD Dr. med. Matthias FröhlichSpecialist in internal medicine, immunology and emergency medicine

This description is based on the public trial registry (NCT05114330) and was translated into plain language by our medical editorial team. Whether participation is an option for you is a decision you make together with your treating physician.